Differentiated thyroid carcinoma is the most common endocrinological malignancy with an increasing incidence over the last 30 years, with women being more frequently affected. In indicated cases, total thyroidectomy followed by adjuvant radioiodine administration is performed, despite current trends towards less aggressive treatment. We would like to investigate the possible adverse effects of radioiodine (RAI) on ovarian function using a simple serum biomarker. Anti-Müllerian hormone (AMH) appears to be the best endocrine marker for assessing physiological age-related oocyte loss for healthy women. The aim of our ongoing prospective study is to determine serum AMH to estimate ovarian reserve for premenopausal women treated with RAI. Over the course of one year, 33 serum samples from women with thyroid cancer and 3 serum samples from healthy women were examined. AMH levels were compared before radioiodine treatment and at regular intervals after treatment. Mean of the AMH level was 5.4 ng/ml (n=33) prior to RAI. The average level of AMH decreased to 1.8 ng/ml in 4-6 months after treatment. In 22.2 % of patients AMH dropped to 0 ng/ml from a non-zero value. Thereafter, we observed an increase in AMH, the average value was 2.7 ng/ml in 8-12 months. We demonstrated a significant decrease in AMH shortly after radioiodine treatment and a subsequent trend of increase at one year after treatment. Consequently, predicting the adverse effects of radioiodine by assessing a serum biomarker could help to select an appropriate treatment strategy for young women planning pregnancy.

The 4th Department of Internal Medicine Hematology University Hospital Hradec Králové and Charles University Faculty of Medicine in Hradec Králové Hradec Králové Czech Republic

Zobrazit více v PubMed

Weeks S, Grossman CE. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing; 2023. Sodium Iodide I 131. [Updated 2023 Feb 13] p. Jan. Available from: https://www.ncbi.nlm.nih.gov/books/NBK556145/ PubMed

Vlček P, Nováková D, Vejvalka J, Zimák J, Křenek M, Vošmiková K, Smutný S, et al. Draft of the best medical treatment in patients with low-risk thyroid cancer (Article in Czech) Vnitr Lek 201561769–777.. PubMed

Hána V. Endokrinologie pro Praxi. 2. ed. Praha: Maxdorf; 2019. Nádory štítné žlázy; pp. 115–116.

Evranos B, Faki S, Polat SB, Bestepe N, Ersoy R, Cakir B. Effects of Radioactive Iodine Therapy on Ovarian Reserve: A Prospective Pilot Study. Thyroid. 2018;28:1702–1707. doi: 10.1089/thy.2018.0129. PubMed DOI

Wong QHY, Anderson RA. The role of antimullerian hormone in assessing ovarian damage from chemotherapy, radiotherapy and surgery. Curr Opin Endocrinol Diabetes Obes. 2018;25:391–398. doi: 10.1097/MED.0000000000000447. PubMed DOI PMC

Deswal R, Narwal V, Dang A, Pundir CS. The Prevalence of Polycystic Ovary Syndrome: A Brief Systematic Review. J Hum Reprod Sci. 2020;13:261–271. doi: 10.4103/jhrs.JHRS_95_18. PubMed DOI PMC

Moolhuijsen LME, Visser JA. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020;105:3361–3373. doi: 10.1210/clinem/dgaa513. PubMed DOI PMC

Sun H, Mao H, Cai J, Zhao Y. Research progress on anti-mullerian hormone clinical applications and immunoassay development. Front Lab Med. 2018;2:14–18. doi: 10.1016/j.flm.2018.02.002. DOI

Josso N, Rey RA. What Does AMH Tell Us in Pediatric Disorders of Sex Development? Front Endocrinol (Lausanne) 2020;11:619. doi: 10.3389/fendo.2020.00619. PubMed DOI PMC

Lebl J, Taji EA, Koloušková S, Průhová Š, Šnajderová M, Šumník Z. Dětská Endokrinologie a Diabetologie. 1. ed. Galén, Praha; 2016. pp. 315–319.

Rajpert-De Meyts E, Jørgensen N, Graem N, Müller J, Cate RL, Skakkebaek NE. Expression of anti-Müllerian hormone during normal and pathological gonadal development: association with differentiation of Sertoli and granulosa cells. J Clin Endocrinol Metab. 1999;84:3836–3844. doi: 10.1210/jc.84.10.6047. PubMed DOI

Victoria M, Labrosse J, Krief F, Cédrin-Durnerin I, Comtet M, Grynberg M. Anti Müllerian Hormone: More than a biomarker of female reproductive function. J Gynecol Obstet Hum Reprod. 2019;48:19–24. doi: 10.1016/j.jogoh.2018.10.015. PubMed DOI

Feyereisen E, Lozano DHM, Taieb J, Hesters L, Frydman R, Fanchin R. Anti-Müllerian hormone: clinical insights into a promising biomarker of ovarian follicular status. Reprod Biomed Online. 2006;12:695–703. doi: 10.1016/S1472-6483(10)61081-4. PubMed DOI

Marek J, Hána V. Endokrinologie. 1 ed. Galén, Praha; 2017. pp. 387–389.

Zec I, Tislaric-Medenjak D, Bukovec Megla Z, Kucak I. Anti-Müllerian hormone: A unique biochemical marker of gonadal development and fertility in humans. Biochem Med (Zagreb) 2011;21:219–230. doi: 10.11613/BM.2011.031. PubMed DOI

Vlček P, Nováková D, Katra R. Thyroid carcinomas: the present view on diagnostics and therapy. (Article in Czech) Vnitr Lek. 2017;63:572–579. doi: 10.36290/vnl.2017.115. PubMed DOI

Dietlein M, Grünwald F, Schmidt M, Schneider P, Verburg FA, Luster M. Radioiodine therapy for benign thyroid diseases (version 5). German Guideline. Nuklearmedizin. 2016;55:213–220. doi: 10.3413/Nukmed-0823-16-04. PubMed DOI

Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJG, Tennvall J, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. J Nucl Med Mol Imaging. 2008;35:1941–1959. doi: 10.1007/s00259-008-0883-1. PubMed DOI

Jankowska K. Premature ovarian failure. Prz Menopauzalny. 2017;16:51–56. doi: 10.5114/pm.2017.68592. PubMed DOI PMC

Kučera R, Topolčan O, Rumpíková T, Rumpík D, Dostál J.Determination of anti-Müllerian hormone in women (Article in Czech) Ceska Gynekol 201378282–288.. PubMed

Wu JX, Young S, Ro K, Li N, Leung AM, Chiu HK, Harari A, Yeh MW. Reproductive outcomes and nononcologic complications after radioactive iodine. Thyroid. 2015;25:133–138. doi: 10.1089/thy.2014.0343. PubMed DOI PMC

Barbakadze L, Kristesashvili J, Khonelidze N, Tsag G. The Correlations of Anti-Mullerian Hormone, Follicle-Stimulating Hormone and Antral Follicle Count in Different Age Groups of Infertile Women. Int J Fertil Steril. 2015;8:393–398. doi: 10.22074/ijfs.2015.4179. PubMed DOI PMC

Vrontikis A, Chang PL, Kovacs P, Lindheim SR. Antral follice counts (AFC) predict ovarian response and pregnancy outcomes in oocyte donation cycles. J Assist Reprod Genet. 2010;27:383–389. doi: 10.1007/s10815-010-9421-8. PubMed DOI PMC

Moolhuijsen LME, Visser JA. Anti-Müllerian Hormone and Ovarian Reserve: Update on Assessing Ovarian Function. J Clin Endocrinol Metab. 2020;105:3361–3373. doi: 10.1210/clinem/dgaa513. PubMed DOI PMC

Krassas G, Pontikides N, Kaltsas T, Papadopoulou P, Paunkovic J, Paunkovic N, Duntas LH. Disturbances of menstruation in hypohyroidism. Clin Endocrinol (Oxf) 1999;50:655–659. doi: 10.1046/j.1365-2265.1999.00719.x. PubMed DOI

Aghajanova L, Lindeberg M, Carlsson IB, Stavreus-Evers A, Zhang P, Scott JE, Hovatta O, Skjöldebrand-Sparre L. Receptors for thyroid-stimulating hormone and thyroid hormones in human ovarian tissue. Reprod Biomed Online. 2009;18:337–347. doi: 10.1016/S1472-6483(10)60091-0. PubMed DOI